文献类型：期刊文献

中文题名：血脂康胶囊治疗颈动脉粥样硬化临床随机对照试验的meta分析

英文题名：Meta-analysis of clinical randomized controlled trials of Xuezhikang Capsules in the treatment of carotid atherosclerosis

作者：张红[1];卢玉俊[1,2];苏华[1];程雪岩[1]

第一作者：张红

机构：[1]甘肃中医药大学中西医结合学院,甘肃兰州730000;[2]甘肃中医药大学附属医院心血管二科,甘肃兰州730000

第一机构：甘肃中医药大学中西医结合学院

年份：2025

卷号：22

期号：23

起止页码：1

中文期刊名：中国医药导报

外文期刊名：China Medical Herald

基金：国家重点研发计划项目(2018YFC1705604);第七批全国老中医药专家学术经验传承项目(国中医药办人教函[2021]272号)。

语种：中文

中文关键词：血脂康胶囊;颈动脉粥样硬化;系统评价;meta分析

外文关键词：Xuezhikang Capsules;Carotid atherosclerosis;Systematic review;Meta-analysis

摘要：目的系统评估血脂康胶囊治疗颈动脉粥样硬化(CAS)的有效性与安全性。方法计算机检索中国知网、万方数据知识服务平台、维普网、中国生物医学文献数据库、Pub Med、Embase、The Cocharane Library及Web of Science核心合集数据库中血脂康胶囊治疗CAS的随机对照试验,检索时间为建库至2025年3月。对文献数据进行提取,采用Cochrane系统评价手册5.1.0中的风险偏倚评估工具展开偏倚风险评价,并利用Rev Man 5.4.1软件进行meta分析。结果最终共纳入7项随机对照试验,涉及909例患者,其中治疗组457例,对照组452例。文献质量评价方面,研究证据偏倚风险较大。meta分析结果显示,治疗组甘油三酯水平低于对照组,差异有统计学意义[MD=-0.36,95%CI(-0.49,-0.22),P<0.00001];治疗组总胆固醇水平低于对照组,差异有统计学意义[MD=-0.93,95%CI(-1.17,-0.70),P<0.00001];治疗组低密度脂蛋白胆固醇水平低于对照组,差异有统计学意义[MD=-0.90,95%CI(-1.34,-0.47),P<0.0001];治疗组颈动脉内膜中层厚度低于对照组,差异有统计学意义[MD=-0.24,95%CI(-0.47,-0.02),P=0.03];治疗组斑块Crouse积分低于对照组,差异有统计学意义[MD=-1.32,95%CI(-1.99,-0.64),P=0.0001];所有研究均未发现严重心脑血管不良事件的报告。结论血脂康胶囊可有效改善CAS患者的血脂水平及颈动脉病变情况,提高CAS的临床疗效,且不良反应较少。然而,因纳入文献大部分无详细的随机化、盲法实施记录,加之疗程差异大,仍然存在较大的偏倚风险。
Objective To systematically evaluate the efficacy and safety of Xuezhikang Capsules in the treatment of carotid atherosclerosis(CAS).Methods The randomized controlled trials of Xuezhikang Capsules in the treatment of CAS were retrieved by computer from CNKI,Wanfang Data,VIP,Chinese Biomedical Literature Database,PubMed,Embase,the Cocharane Library,and Web of Science core collection database,and the search period was from database establishment to March 2025.The literature data were extracted,and the risk of bias assessment was conducted using the risk bias assessment tool in Cochrane Manual of Systematic Reviews 5.1.0,and meta-analysis was performed using RevMan 5.4.1 software.Results A total of 7 randomized controlled trials were ultimately included,involving 909 patients,including 457 in the treatment group and 452 in the control group.In terms of the evaluation of literature quality,the risk of bias in research evidence was relatively high.The results of the meta-analysis showed that the level of triglyceride in the treatment group was lower than that in the control group,and the difference was statistically significant(MD=-0.36,95%CI[-0.49 to-0.22],P<0.00001);the level of total cholesterol in the treatment group was lower than that in the control group,and the difference was statistically significant)MD=(-0.93,95%CI[-1.17 to-0.70],P<0.00001);the level of low-density lipoprotein cholesterol in the treatment group was lower than that in the control group,and the difference was statistically significant(MD=-0.90,95%CI[-1.34 to-0.47],P<0.0001);carotidintima-media thickness in the treatment group was lower than that in the control group,and the difference was statistically significant(MD=-0.24,95%CI[-0.47 to-0.02],P=0.03);and the Crouse score of plaques in the treatment group was lower than that in the control group,and the difference was statistically significant(MD=-1.32,95%CI[-1.99 to-0.64],P=0.0001);and no serious adverse cardiovascular and cerebrovascular events were reported in all studies.Conclusion Xuezhikang Capsules can effectively improve lipid levels and carotid artery lesions status in CAS patients,and improve the clinical efficacy of CAS with fewer adverse effects.However,as most of the included literature lacks detailed records of randomization and blinding implementation,and there are significant differences in treatment courses,there is still a considerable risk of bias.